| Study |
Reference |
|
Bateman, 2016
|
Bateman Late Pregnancy Beta Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. Pediatrics 2016; 138:
|
|
Bergman, 2018
|
Bergman Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies: A European Case-Malformed Control Study. Drug Saf 2018; 41:415-427
|
|
Caton, 2009
|
Caton Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension 2009; 54:63-70
|
|
Chan, 2010
|
Chan WS Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. Hypertens Pregnancy 2010;29:271-83
|
|
Cruickshank, 1990
|
Cruickshank Atenolol in essential hypertension during pregnancy. BMJ 1990; 301:1103
|
|
Cruickshank, 1991
|
Cruickshank Maternal Obstetric Outcome Measures in A Randomised Controlled Study of Labetalol in the Treatment of Hypertension in Pregnancy, Clinical and Experimental Hypertension. Part B: Hypertension in Pregnancy, 1991, 10:3, 333-344.
|
|
Delteil, 2024
|
Delteil Beta-blockers and pregnancy - An EFEMERIS study Scientific report. 2024: 1-67.
|
|
Duan, 2018
|
Duan Beta-blocker subtypes and risk of low birth weight in newborns. J Clin Hypertens (Greenwich) 2018; 20:1603-1609
|
|
Fisher, 2017
|
|
|
Fitton (Controls unexposed, disease free), 2020
|
Fitton In Utero Antihypertensive Medication Exposure and Neonatal Outcomes: A Data Linkage Cohort Study. Hypertension 2020; 75:628-633
|
|
Fitton (Controls unexposed, sick), 2020
|
Fitton In Utero Antihypertensive Medication Exposure and Neonatal Outcomes: A Data Linkage Cohort Study. Hypertension 2020; 75:628-633
|
|
Petersen, 2012
|
Petersen Beta-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. BMJ Open 2012; 2:
|
|
Sibai, 1990
|
Sibai A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990; 162:960-6; discussion 966-7
|
|
Thewissen (Controls unexposed, disease free), 2017
|
Thewissen Neonatal haemodynamic effects following foetal exposure to labetalol in hypertensive disorders of pregnancy. J Matern Fetal Neonatal Med 2017; 30:1533-1538
|
|
Thewissen (Controls unexposed, sick), 2017
|
Thewissen Neonatal haemodynamic effects following foetal exposure to labetalol in hypertensive disorders of pregnancy. J Matern Fetal Neonatal Med 2017; 30:1533-1538
|
|
Van Zutphen, 2014
|
Van Zutphen AR Maternal hypertension, medication use, and hypospadias in the National Birth Defects Prevention Study. Obstet Gynecol 2014;123:309-17
|
|
Xiang, 2020
|
Xiang Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. Cell Mol Biol (Noisy-le-grand) 2020; 66:9-13
|
